Top medics issue urgent warning over heart drug taken by millions - as makers AstraZeneca are accused of 'misreporting' safety data
Anti-clotting pill ticagrelor was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack.
The twice-daily pill, sold as Brilinta, is given to people with acute coronary syndrome —a sudden reduction of blood to the heart—reducing the risk of deadly clots and strokes.
Since then, studies have questioned if the AstraZeneca drug is as good as its rivals, such as clopidogrel, with some even suggesting it may even increase the risk of bleeding.
Now, experts have discovered 'evidence of serious misreporting' in two clinical trials, pivotal to getting the drug approved in the UK and US, 'raising doubts over its approval'.
The BMJ investigation claimed the 'primary endpoint' results—the key measure to determine whether a treatment is effective—for both trials were inaccurately reported in leading cardiology journal Circulation.
It also said around a quarter of the readings from machines used in the trials were not included in the data sets, the US medicine's regulator, the Food and Drug Administration (FDA) used to approve the drug.
Dr Victor Serebruany, an expert in cardiovascular pharmacology at Johns Hopkins University in Maryland, who has been critical of the drug for over a decade said: 'It's been obvious for years that there is something wrong with the data.
Since then, studies have questioned if the AstraZeneca drug is as good as its rivals, such as clopidogrel, with some even suggesting it may even increase the risk of bleeding
'That the FDA 's leadership could look past all these problems—on top of the many problems their own reviewers identified and are now being discovered by The BMJ—is unconscionable.
'We all need to know how and why that happened.
'If doctors had known what happened in these trials, they would never have started using ticagrelor.'
In order for ticagrelor to get approved, clinical trials had to prove that it was a better drug than competitors in a phase 3 trial.
After phase 3 and drug approval, the FDA and MHRA in the UK, continues monitoring it in phase 4 trials, to see if there are any additional problems with the drug.
But the BMJ analysis of two phase 2 trial results found there were instances of patients who's blood 'platelet aggregation dramatically increased'.
This is where platelets—a type of blood cell—stick together to form clumps which can lead to blood clots, exactly what the drug aims to prevent.
It 'suggests incorrect laboratory readings', the BMJ said.
Assessing the readings from platelet machines used at the two trial sites, led by cardiologist Dr Paul Gurbel, they also found more than 60 of the 282 readings were not included in the datasets submitted to the FDA.
'The platelet activity levels not entered were significantly higher than those used in the Circulation papers and FDA datasets,' they claimed.
'It is unclear whose blood was sampled, and why those measurements did not contribute to data in either trial.'
A spokesperson for the Sinai Center for Thrombosis Research and Drug Development, which Dr Gurbel leads, said: 'Any allegations of any research misconduct in the two studies are baseless and erroneous.'
In the UK, the drug is prescribed around 45,000 times per month on the NHS.
According to medicines watchdog the National Institute for Health and Care Excellence (NICE), patients are advised to take the drug twice a day at 90mg for around a year after a heart attack.
A lower dose of 60mg, may then be prescribed by doctors for up to a further three years.
It may also be taken by those who have suffered a minor stroke or a transient ischaemic attack at 90mg alongside aspirin.
The body naturally forms blood clots in order to patch wounds and stop bleeding.
But over time, things like age, smoking and excessive weight gain can make blood clots more common.
These kinds of clots also become more common after someone has a heart attack or blood vessel disorder, coronary artery disease.
When someone overproduces these clots they can clog blood vessels, interrupting blood flow or weakening the walls of blood vessels, causing aneurysms and heart attacks.
Circulation and AstraZeneca did not respond to a request for comment from the BMJ. MailOnline has also approached AstraZeneca for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Rhyl Journal
5 minutes ago
- Rhyl Journal
Dermot Murnaghan ‘fell through the gaps' with stage four cancer diagnosis
The broadcaster, 67, announced his diagnosis with stage four prostate cancer in June, saying he was 'responding positively' to treatment. Speaking at an event for Prostate Cancer UK, the broadcaster shared his diagnosis journey and urged men to get tested. He said: 'For years I thought 'that will do me' I'm getting tested basically once a year or every couple of years. 'It never occurred to me that they weren't testing for PSA (prostate-specific antigen) and I never went to my GP because I was getting other tests privately through the production company. 'So that's how I fell through the gaps and that's how I had a massive wake-up call and want to share the message.' Stage four prostate cancer can mean that the cancer has spread into different parts of the body including nearby body organs, such as the back passage or bladder, and other parts of the body outside the pelvis, such as the bones, lungs or liver, according to the Cancer Research UK website. About one in eight men will get prostate cancer in their lifetime, according to the charity Prostate Cancer UK, however, there currently are no screening programmes for men to get tested. One option is a PSA blood test which checks the level of prostate-specific antigens in the blood. A high reading may be a sign of a prostate condition. NHS guidance says these tests are not routinely used as they are not reliable, but men over 50 can ask GPs for one. Murnaghan added: 'You can get to the stage I have with no symptoms. 'Get the test, insist on the test. You can insist on the test if you are in a high-risk group and under 50. If you are not, I'd still get the test at 50. 'Go to your GP and they say you don't need it but say 'but I want it'. It is your right to have it. Just keep doing that every year or couple of years. Once you've got that marker where your PSA is, keep monitoring it. 'The earlier you find prostate cancer the easier it is to treat, so check your risk in just 30 seconds with Prostate Cancer UK's online risk checker to see if you are at risk and what you can choose to do about it.' The presenter also shared an update on his treatment, adding that 'there is a lot of hope' with new trials and options available. He said: 'In terms of the treatments for the stage I'm at, they are a myriad. What's astonishing is just how fast things are developing, even at last stage advanced prostate cancer, the treatment I'm on, the programme that I've been getting only really was approved within the last couple of years. 'There is a lot of hope out there, there's a lot going on, there's a lot of advice and a lot of things happening there. So as a sufferer and a non-medical person my advice is, ask questions. There are always different ways of doing things, slightly, but just keep asking those questions about where you are, what there is available or even if perhaps you could access one of those clinical trials yourself.' The broadcaster will join Sir Chris Hoy's fundraising charity bike ride, Tour de 4, to raise awareness and funds for chancer charities across the UK. The Olympian announced he had a terminal diagnosis for prostate cancer in October 2024. Murnaghan added: 'I'm really proud to be supporting Prostate Cancer UK and taking part in Sir Chris Hoy's fundraising event, the Tour de 4. This groundbreaking cycling challenge is raising vital funds for cancer charities and changing the conversation. 'I'll be riding in Glasgow this September alongside some incredible participants, all to raise awareness and help save men's lives. Prostate Cancer UK means a lot to me and I'd love for you to get involved and show your support. Together we can make a real difference.'
The Independent
6 minutes ago
- The Independent
Government urged to introduce ‘statutory' regulations
The David Fuller inquiry has found Government 'must' introduce statutory regulations to protect the 'security and dignity' of people after death. The current regulatory system is 'piecemeal' and there are no organisations that focus solely on protecting the dignity of the deceased, the inquiry has found. In total, the inquiry, chaired by Sir Jonathan Michael, has made 75 key recommendations to address arrangements in England for the care of people after death. The inquiry was opened after necrophiliac killer David Fuller abused at least 100 deceased women and girls over a 15 year period without being detected. On Tuesday, Sir Jonathan announced that with the current arrangements, crimes like Fuller's could happen again because existing regulatory bodies do not ensure the 'security and dignity' of the deceased. The inquiry has found: 'There is no regulator or regulatory or oversight framework with the overriding objective of protecting the security and dignity of the deceased.' It added: 'The current system of regulation and oversight is partial, piecemeal and not universally mandated in its application to the issues examined by the inquiry.' The Human Tissue Authority (HTA) have jurisdiction over post-mortem examinations and laboratory work but none over body stores or the funeral sector. This, the inquiry explained, is because the HTA defines human tissue as 'material that has come from a human body' rather than the body itself. The HTA, along with other organisations such as the Care Quality Commission, United Kingdom Accreditation Service and NHS England, all have important roles around this provision, but none have the 'primary objective' of protecting the 'security and dignity' of the deceased. The inquiry acknowledged that actions taken by these organisations in response to David Fuller are 'well-intentioned' but fail to address the underlying issues. The report read: 'While the actions that those with a role in regulation and oversight of organisations that store deceased people have taken in response to the crimes of David Fuller and the Inquiry's Phase 1 Report are well-intentioned and welcome, 'They are unable to address the underlying issue that regulation and oversight are partial. 'They do not extend to every institution where deceased people are stored. Fundamentally, there is no regulator or system of oversight with the primary objective of protecting the security and dignity of the deceased.' On top of this, no organisation holds specific powers to stop a funeral director from operating in the event of 'poor practice, misconduct or neglect' which fell short of a criminal standard, the inquiry found. In 2019, the Competition and Markets Authority (CMA) began an investigation into oversight of activity in funeral directors' premises. When published in December 2020, it contained a recommendation that the UK government establish an inspection regime to help curtail these issues. On Tuesday, the inquiry noted: 'It is very disappointing that, over five years ago, the CMA made the recommendation that the government should establish an inspection and registration regime for the funeral industry and yet, to date, no decisive action has been taken to implement this recommendation and address the manifest weaknesses in the sector.'
The Independent
11 minutes ago
- The Independent
Why the UK is lagging behind other countries on measles vaccinations
The UK is the worst-performing G7 country for coverage of measles vaccines, as rates lag behind Europe, with experts warning declining health budgets and the spread of misinformation are putting children at risk. Now, health officials in the UK have sounded the alarm over our waning vaccine coverage after a child with measles died in Liverpool. On Monday, health secretary Wes Streeting said that the child's death shows the nation needs to 'redouble its efforts' to vaccinate more children and said improvements promised in the NHS's 10-year plan, such as giving parents access to digital health records, could help. One expert told The Independent a multitude of issues have impacted the UK's measles vaccination rates, including declining public health budgets, lower access to GP services, and the increased circulation of misinformation on social media. How does the UK compare to other G7 countries? Data published by the World Health Organisation (WHO) and the charity UNICEF estimates the UK has just 89 per cent coverage of the first measles vaccine in 2024 and 85 per cent coverage of the second dose. This is down from 93 per cent a decade earlier and well below WHO target of 95 per cent, which it said is needed to effectively eliminate the spread of the disease in the community. And we're lagging well behind our G& counterparts, with vaccine rates in Germany the highest (96 per cent), Italy and France (95 per cent) and Japan (94 per cent)/. The organisations warned that the global rates of childhood vaccinations are falling, with 30 million children unvaccinated. Rates of the first MMR vaccine across the UK have been in decline since 2014. An analysis by the Nuffield Trust of 2023-24 data shows England lags behind Wales, Scotland and Northern Ireland on coverage of this vaccine. Within England, London has the worst coverage by far, with just 81 per cent of children having received a first course by their second birthday. Data as of June 2025 shows that the capital accounted for 44 per cent of all measles cases. Measles is a highly contagious, serious airborne disease caused by a virus that can lead to severe complications and death. Dr Connor Bamford, Virologist, Queen's University Belfast, explained: 'Various conditions can make individuals more vulnerable to severe measles. This may include immunosuppressed individuals undergoing cancer treatment for example who, because of their condition, have lost immunity to the virus, even if they have been vaccinated." He said: "We do see children and adults dying from measles in the UK and the last young person who died was reported in 2024. In 2023, we saw another child die of a disease called SSPE (subacute sclerosing panencephalitis), which is a fatal complication of measles that occurs years after an earlier infection. In 2023 two adults also died." In the UK, immunisation against it is typically given as part of the MMR vaccine for measles, mumps and rubella. According to the NHS, around 99 per cent of people who receive the MMR vaccine will be protected against measles and rubella. Meanwhile, around 88 per cent will be protected against mumps, and anyone who does get it after vaccination will experience milder symptoms. What has impacted vaccine uptake in the UK? According to the Nuffield Trust, uptake of the MMR vaccine decreased significantly following a now discredited article by Dr Andrew Wakefield in 1998, which linked MMR vaccination to autism. By 2003-04 uptake of the vaccine had dropped to 80 per cent. However, coverage then improved and hit 93 per cent in 2013-14, before dropping again to 89 per cent in 2023-24. A recent survey by the UK Health Security Agency (UKHSA) suggested that overall, parents in the UK have a high level of confidence that vaccines work for children, with 87 per cent of those surveyed having agreed with this. However, vaccine coverage for MMR and other key childhood vaccines has declined in recent years, and now health officials are urging parents to get their children vaccinated. Speaking with The Independent, Adam Finn, Professor of Paediatrics at the University of Bristol, and a member of the government's Joint Vaccinations and Immunisations Committee, explained there were several factors, including the fact that there has been a general decline in immunisation over the past 15 years, which had initially been ignored. He said: 'The public health authority officials favour the idea that it's because there's been a waning of resource in the health service to deliver the vaccine programme, so as primary care in particular has become more stretched the capacity to chase people up and go after the people that are otherwise not getting their act together has disappeared and that's resulted in the vulnerable edge getting worse and worse.' 'The competing hypothesis, which is quite convenient for the politicians, is that it's mad internet misinformation, and in a sense, people are somehow to blame for believing it and that it's not really a governmental problem, it's myth and legend, as it were.' 'My view is that those two things are not mutually exclusive.' He said while there are a group of parents and people who avoid vaccination, there are another group who don't do it because they're not aware, or it's not high up on their priority list. The professor of paediatrics also suggested that vaccines, such as MMR, were a victim of their own success, with the public no longer having a living memory of the severe and life-threatening impacts of the disease. In the 1960s, people would've queued around the block to get their children immunised because they were afraid of them dying of those diseases where whereas now they've never heard of them, he said. Possible solutions? One key solution is enabling healthcare workers, such as GPs or health visitors, to have conversations around vaccines with parents, says Professor Finn. 'The government has come in with a mission to solve the problem of the under-resourced health service and has emphasised the way it wants to do that is to stop people from getting ill rather than build more hospitals. 'And one of the most obvious and effective, proven and countable ways of doing that is to ensure vaccine programmes are delivered, and so I think it should be a fairly open and closed argument that this is where Wes Streeting needs to put his money.' Where access to GPs and health visitors is an issue, experts have suggested expanding the list of places where parents can get vaccines, and information about them could help. Malcolm Harrison, Chief Executive of the Company Chemists' Association (CCA), has suggested pharmacies could assist. He said last year, a pilot in the North West of England allowed children aged 5 to 11 who had missed doses to get the MMR vaccine at their local pharmacy for the first time. Experts have also suggested that schools could be an important place for children's vaccines to be accessed.
